No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Gibbel: Gibel 2024 Annual Results Express Announcement
Gibel 2024 Annual Results Express Announcement
Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SH): Not yet connected to the AI platform.
On February 18, Glonghui reported that Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SH) stated on the investor interaction platform that according to the company's preparation and disclosure plan for the 2024 annual report, the annual report will be disclosed on April 15, 2025. The company will disclose the 2024 annual performance report in accordance with relevant regulations by the end of February 2025, please pay attention. According to the company's current plan, the Phase III clinical trial for the new antidepressant JJH201501 is expected to complete the enrollment of subjects by the end of March 2025, and after enrollment, follow-up observations and data sorting will be conducted, with the completion of Phase III expected by the end of 2025.
Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SH): Director Hu Tao plans to hold a Shareholding of no more than 1%.
On February 6, Gelonghui reported that Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SH) announced that the Director Hu Tao issued a "Shareholding Reduction Plan Notification Letter", with the main content as follows: Hu Tao plans to reduce his holdings of the company's shares by no more than 1.99 million shares through competitive trading or block trading, accounting for no more than 1.00% of the company's total share capital. The reduction period is from March 3, 2025 to May 30, 2025, and the reduction price will be determined according to market prices.
Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SH): Diclofenac Acyloxyethyl Acetic Acid Tablets received the Pharmaceutical registration certificate.
Gelonghui reported on January 22 that Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SH) announced the receipt of the "Pharmaceutical Registration Certificate" issued by the National Medical Products Administration. The drug's generic name is Chlorofenamic Acid Tablets. The indications for this drug are for the treatment of symptoms caused by osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, such as pain and inflammation. Chlorofenamic acid is a non-steroidal anti-inflammatory drug with extensive clinical applications in the treatment and relief of pain, showing significant anti-inflammatory, analgesic, and antipyretic effects. The dosage form previously marketed by the company was enteric-coated tablets, while the dosage form approved this time is tablets.
Could The Market Be Wrong About Jiangsu Jibeier Pharmaceutical Co., Ltd. (SHSE:688566) Given Its Attractive Financial Prospects?
